Ovid Therapeutics Inc. financial data

Symbol
OVID on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 486% % -36%
Debt-to-equity 38% % -23%
Return On Equity -64% % -62%
Return On Assets -46% % -76%
Operating Margin -618% % 94%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71,212,353 shares 0.28%
Common Stock, Shares, Outstanding 71,151,981 shares 0.2%
Entity Public Float $45,900,000 USD -76%
Common Stock, Value, Issued $71,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 70,975,778 shares 0.51%
Weighted Average Number of Shares Outstanding, Diluted 70,975,778 shares 0.51%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $6,610,000 USD 946%
Research and Development Expense $24,927,000 USD -40%
General and Administrative Expense $22,554,000 USD -21%
Operating Income (Loss) $40,871,000 USD 41%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $36,331,000 USD -12%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $36,331,000 USD -12%
Earnings Per Share, Basic 0 USD/shares 33%
Earnings Per Share, Diluted 0 USD/shares 33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $20,611,000 USD 37%
Cash, Cash Equivalents, and Short-term Investments $25,603,000 USD -59%
Assets, Current $28,824,000 USD -56%
Property, Plant and Equipment, Net $269,000 USD -47%
Operating Lease, Right-of-Use Asset $11,916,000 USD -8.9%
Other Assets, Noncurrent $0 USD -100%
Assets $63,848,000 USD -38%
Accounts Payable, Current $1,710,000 USD -37%
Employee-related Liabilities, Current $1,849,000 USD -57%
Accrued Liabilities, Current $2,959,000 USD -61%
Liabilities, Current $6,796,000 USD -42%
Operating Lease, Liability, Noncurrent $12,354,000 USD -10%
Liabilities $19,150,000 USD -27%
Accumulated Other Comprehensive Income (Loss), Net of Tax $126,000 USD -450%
Retained Earnings (Accumulated Deficit) $331,376,000 USD -12%
Stockholders' Equity Attributable to Parent $44,698,000 USD -41%
Liabilities and Equity $63,848,000 USD -38%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,280,000 USD 38%
Net Cash Provided by (Used in) Financing Activities $13,000 USD -94%
Net Cash Provided by (Used in) Investing Activities $5,102,000 USD -75%
Common Stock, Shares Authorized 125,000,000 shares 0%
Common Stock, Shares, Issued 71,151,981 shares 0.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $22,542,000 USD 33%
Deferred Tax Assets, Valuation Allowance $89,474,000 USD -3.4%
Depreciation $256,000 USD -35%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $36,482,000 USD -12%
Lessee, Operating Lease, Liability, to be Paid $17,557,000 USD -12%
Operating Lease, Liability, Current $1,409,000 USD 7.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,316,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,316,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,469,000 USD 6.6%
Deferred Tax Assets, Operating Loss Carryforwards $62,120,000 USD 12%
Preferred Stock, Shares Issued 1,250 shares 0%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,469,000 USD 0%
Additional Paid in Capital $376,129,000 USD 1.3%
Preferred Stock, Shares Outstanding 1,250 shares 0%
Amortization of Intangible Assets $147,000 USD 8.9%
Depreciation, Depletion and Amortization $141,000 USD 3.7%
Share-based Payment Arrangement, Expense $4,871,000 USD -28%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%